Primary biliary cirrhosis, known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis includes itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings.
Primary biliary cirrhosis develops over time and may cause the liver to stop working completely in later stages. Most people are diagnosed early, before the disease progresses. Delay in treatment of cirrhosis can cause liver failure and a liver transplant is necessary for survival. Diagnostic tests for primary biliary cirrhosis includes examination of elevated levels of IgM immunoglobulin levels, lipids, cholesterol and bilirubin, liver biopsy, ultrasonography, CT scanning or MRI. Increasing research and development activities and rising incidence of primary biliary cirrhosis is expected to be a major driver for growth of the Primary Biliary Cirrhosis Drugs Market.
Primary Biliary Cirrhosis Drugs Market – Driver
Currently, only two FDA approved drugs, Ursodeoxycholic acid and Ocaliva, are available in market to reduce cirrhosis progression. However, large number of drugs are in clinical trials and this is expected to propel growth of the primary biliary cirrhosis drug market in the near future. For instance, in 2017, NGM Biopharmaceuticals, Inc. completed phase II clinical trials for its candidate drug NGM 282, an engineered variant of human hormone FGF19, to eliminate bile acid toxicity in primary biliary cirrhosis patients. NGM282 has a unique opportunity to leverage the dual targets of FGF19 without the potential non-tumorigenic property.
Read More@ https://bit.ly/3DAL6Io
